Pertuzumab Granted Priority Review for Neoadjuvant HER2-Positive Breast Cancer

Last week, the FDA announced that it would grant priority review to pertuzumab (Perjeta), as a neoadjuvant treatment for women with HER2-positive early-stage breast cancer.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news

Related Links:

ConclusionsHigh Ki-67 is a strong predictor for pCR in HER2+  breast cancer. TIL and FOXP3 T cells may play a role in tumor response in HER2+ cancer. PD-L1 is expressed in a subset of HER2+ breast cancer, supporting a role of immunotherapy in treating a subset of HER2+ breast cancers. The role of PD-L1, TIL, and other markers of immunogenicity as pred ictors of response to neoadjuvant chemotherapy in HER2+ breast cancer should be further evaluated.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsGenomic analysis of paired pre- and post-therapy samples resulting from neoadjuvant therapy provides a powerful method for identification of mediators of response. Genes we identified should be assessed as predictive markers or targets in chemo-sensitization.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Condition:   Breast Cancer,Her2 Positive Interventions:   Drug: Albumin binding paclitaxel+ trastuzumab+ patuzumab;   Drug: Docetaxel+ carboplatin+ trastuzumab + patuzumab Sponsor:   Henan Cancer Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer,Her2 Positive Interventions:   Drug: Albumin binding paclitaxel+ trastuzumab+ patuzumab;   Drug: Docetaxel+ carboplatin+ trastuzumab + patuzumab Sponsor:   Henan Cancer Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer,Her2 Positive Interventions:   Drug: Albumin binding paclitaxel+ trastuzumab+ patuzumab;   Drug: Docetaxel+ carboplatin+ trastuzumab + patuzumab Sponsor:   Henan Cancer Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Trastuzumab Biosimilars in the Therapy of Breast Cancer - "Real World" Experiences from four Bavarian University Breast Centres. Geburtshilfe Frauenheilkd. 2020 Sep;80(9):924-931 Authors: Hester A, Gaß P, Fasching PA, Krämer AK, Ettl J, Diessner J, Wöckel A, Egger T, Stock K, Redlin J, Andraschko M, Harbeck N, Würstlein R Abstract Introduction With the introduction of the first trastuzumab biosimilar in the summer of 2018, biosimilar antibodies for breast cancer have found their way into the area of gynaecological oncology. The switch of anti-human epidermal growth factor...
Source: Geburtshilfe und Frauenheilkunde - Category: OBGYN Tags: Geburtshilfe Frauenheilkd Source Type: research
Authors: Sharifi M, Wisinski KB Abstract The management of early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer has evolved in recent years, with the current standard being to tailor the intensity of adjuvant treatment to individual risk. Risk-adapted approaches to systemic therapy have been facilitated both by the recent introduction of multiple novel HER2-targeted therapies and by the development of clinical and pathologic surrogates to enable better prediction of disease behavior. These approaches have been successful at both ends of the disease spectrum. Patients with low-risk tum...
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
CONCLUSION: Our study provides novel insight into clinicopathological characteristics and treatment status among patients with IBC in China, and might provide a direction and basis for further studies. TRIAL REGISTRATION: chictr.org.cn, No. ChiCTR1900027179; http://www.chictr.org.cn/showprojen.aspx?proj=45030. PMID: 32925286 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
Early and accurate assessment of the response to neoadjuvant chemotherapy offers the potential to optimize treatment to obtain improved responses. We aimed to predict the response to neoadjuvant chemotherapy using a second breast core needle biopsy after a median of 2 cycles of neoadjuvant chemotherapy.
Source: Surgery - Category: Surgery Authors: Source Type: research
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Grants | HER2 | Neoadjuvant Therapy | Women